Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

tenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing.

Specifically, certain risks and uncertainties that could cause su
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... the 150 million customer mark, an intense debate continues ... once led by nonprofits. "Microfinance Meets the Market," just ... advances the debate, presenting new research from Jonathan Morduch ... University,s Wagner Graduate School of Public Service, and Robert ...
... better balance in a slippery situation , , FRIDAY, Feb. ... where the footing is unstable helped train them to ... says a University of Illinois at Chicago study. ... develops fall prevention strategies that can be used in ...
... Ill., Feb. 20 Abbott ( NYSE: ABT ) ... from the European Commission for its acquisition of Advanced ... the outstanding shares of common stock of AMO. ... the condition to the tender offer related to European ...
... CHADDS FORD, Pa. and DANBURY, Conn., Feb. 20 ... Pharmaceuticals (Nasdaq: PPCO ) announced today that ... LLC regarding the production and sale of generic formulations ... Endo and Penwest have agreed to dismiss their ...
... FOR RELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, ... Bride, (651) 695-2795, jmacbride@aan.com , Young Smokers Increase ... start smoking before age 17 may increase their risk ... released today that will be presented at the American ...
... Treatment targeting damaged brain areas did not bring significant ... (HealthDay News) -- An experimental laser treatment of ... stroke patients, researchers report. , The trial was the ... stroke. , In the trial, the researchers at the ...
Cached Medicine News:Health News:Research reveals best paths for success as microfinance sector grows 2Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Laser Therapy Disappoints in Stroke Trial 2
Clearview H. pylori II uses rapid, two-step technology for the direct detection of H. pylori antibodies. , ,The patented, innovative technology used by Clearview H. pylori II provides highly sen...
... FlexSure HP is a visually read, ... antibodies to H. pylori, a bacterium that ... with peptic ulcer disease and some gastric ... either whole blood or serum samples, provides ...
... Acceava Mononucleosis test provides superior performance ... a simple procedure that provides an ... with competitive products will convince you ... enable you to deliver improved patient ...
... A rapid test for ... heterophile antibodies specific to infectious ... or whole blood specimens. This ... aid in the diagnosis of ...
Medicine Products: